Company Performance - Benitec Biopharma Limited (BNTC) has returned 23.6% year-to-date, outperforming the Medical sector, which has lost about 4.8% on average [4] - The Zacks Consensus Estimate for BNTC's full-year earnings has increased by 19.7% over the past quarter, indicating improving analyst sentiment [3] Industry Ranking - Benitec Biopharma Limited is part of the Medical - Biomedical and Genetics industry, which includes 503 companies and currently ranks 72 in the Zacks Industry Rank [5] - The Medical - Biomedical and Genetics industry has lost an average of 4.2% so far this year, showing that BNTC is performing better than its industry peers [5] Sector Context - The Medical sector includes 999 companies and is currently ranked 4 in the Zacks Sector Rank, which evaluates sectors based on the average Zacks Rank of individual companies [2] - Another outperforming stock in the Medical sector is Delcath Systems, Inc. (DCTH), which has returned 33.6% year-to-date [4]

Core Viewpoint - Delcath Systems, Inc. (DCTH) has seen a 34.5% increase in share price over the past four weeks, closing at $16.41, with analysts suggesting a potential upside of 48.7% based on a mean price target of $24.40 [1][11]. Price Targets and Analyst Estimates - The mean estimate for DCTH comprises five short-term price targets with a standard deviation of $2.97, indicating a range of estimates from a low of $21 (28% increase) to a high of $29 (76.7% increase) [2][9]. - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Market Sentiment - Analysts are optimistic about DCTH's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which have increased by 3.6% over the past month with no negative revisions [11][12]. - DCTH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, further supporting the potential for upside [13].

Core Viewpoint - The article emphasizes the importance of identifying and maintaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for sustaining momentum in stocks [1]. Group 1: Recent Price Strength Screen - The "Recent Price Strength" screen is a unique short-term trading strategy that helps investors shortlist stocks with strong fundamentals capable of maintaining an uptrend [2]. - Stocks that pass this screen are typically trading in the upper portion of their 52-week high-low range, indicating bullish sentiment [2]. Group 2: Delcath Systems, Inc. (DCTH) - Delcath Systems, Inc. (DCTH) has shown a solid price increase of 19.2% over the past 12 weeks, indicating investor confidence in its potential upside [3]. - DCTH has experienced a price increase of 34.5% over the last four weeks, suggesting that the upward trend is still intact [4]. - Currently, DCTH is trading at 84.7% of its 52-week high-low range, indicating a potential breakout opportunity [4]. Group 3: Fundamental Strength - DCTH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The Zacks Rank system has a strong track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988 [6]. - DCTH also has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [6]. Group 4: Additional Investment Opportunities - Besides DCTH, there are several other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities [7]. - The article encourages exploring over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [7].

Company Performance - Delcath Systems, Inc. (DCTH) reported quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share, compared to a loss of $0.43 per share a year ago, representing an earnings surprise of -70% [1] - The company posted revenues of $19.78 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.24%, and this is a significant increase from year-ago revenues of $3.14 million [2] - Over the last four quarters, Delcath Systems has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - The sustainability of Delcath Systems' stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The stock has lost about 3.6% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] - The current consensus EPS estimate for the coming quarter is $0.08 on revenues of $19.75 million, and for the current fiscal year, it is $0.28 on revenues of $82.26 million [7] Industry Context - The Medical - Instruments industry, to which Delcath Systems belongs, is currently in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5] - Mesa Labs (MLAB), another company in the same industry, is expected to report quarterly earnings of $2.75 per share, with revenues projected to be $63.1 million, reflecting a year-over-year increase of 7.1% [9]

Financial Data and Key Metrics Changes - The company reported a combined revenue of $19,800,000 for Hebsado and ChemoSATs in Q1 2025, with Hebsado sales in the U.S. contributing $18,000,000 and ChemoSATs in Europe adding $1,800,000, compared to $2,000,000 and $1,100,000 respectively in Q1 2024 [7][16] - Gross margins improved to 86% in Q1 2025 from 71% in the same period last year [16] - Net income for Q1 2025 was $1,100,000, a significant turnaround from a net loss of $11,100,000 in Q1 2024 [17] - Positive adjusted EBITDA was reported at $7,600,000 compared to an adjusted EBITDA loss of $7,300,000 in Q1 2024 [17] - The company ended the quarter with approximately $59,000,000 in cash and investments and no debt [8][17] Business Line Data and Key Metrics Changes - The U.S. market for Hebsado and ChemoSATs showed strong growth, with a focus on expanding treatment centers, increasing from 17 to 19 active centers [8][9] - The average treatments per center per month were approximately two in Q1, with expectations to remain just under two for the remainder of the year [10][28] Market Data and Key Metrics Changes - The European market for ChemoSATs grew by 29% over the prior quarter to $1,800,000, although it is not expected to be a significant revenue contributor in the short to medium term due to reimbursement pricing challenges [11] - The company is focusing on generating clinical data from European sites, which have over a decade of experience with ChemoSATs [11][44] Company Strategy and Development Direction - The company aims to expand its active treatment centers to 30 by year-end, with a current pace of opening three to five centers per quarter [9][10] - The strategic focus includes leveraging cash from operations to support research and development initiatives for broader patient populations suffering from liver cancer [8][15] - The company is pursuing additional indications for Hepciddo, including metastatic colorectal and breast cancer, with ongoing clinical trials [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a more even distribution of center activations throughout the year, rather than a concentration in the second half [25] - The company anticipates that the ongoing engagement with oncologists and interventional radiologists will drive demand for treatments [15] - Management acknowledged the competitive landscape but emphasized the collaborative nature of information sharing among treatment centers [38] Other Important Information - The company has implemented a patient access program to assist with copay costs and connect patients with treatment centers [10][53] - The company is managing its European operations on a breakeven basis while focusing on generating clinical data [44] Q&A Session Summary Question: Update on center activations - Management indicated that the pace of center activations may be more even throughout the year than previously anticipated, with potential for two to three additional centers in Q2 [25][26] Question: R&D expenses and EBITDA expectations - R&D expenses are expected to increase significantly, with total operating expenses projected to rise by 60% over 2024, while maintaining positive EBITDA for the year [30][31] Question: Frequency of patient treatments - The average frequency of treatments for patients is expected to remain around 4.1, which is a key driver for overall revenue [36] Question: European market growth and reimbursement - Management noted that while European revenues are increasing, reimbursement challenges remain, and they are focusing on generating clinical data before investing more resources [40][44] Question: Companion diagnostics and potential acquisitions - The company is open to exploring companion diagnostics or synergistic products but has not found suitable opportunities yet [70][72]

Financial Data and Key Metrics Changes - The company reported a combined revenue of $19.8 million for Q1 2025, with Hebsado sales in the U.S. contributing $18 million and ChemoSAT sales in Europe adding $1.8 million, compared to $2 million and $1.1 million respectively in Q1 2024 [5][15] - Gross margins improved to 86% in Q1 2025 from 71% in the same period last year [15] - Net income for Q1 2025 was $1.1 million, a significant turnaround from a net loss of $11.1 million in Q1 2024 [16] - Positive adjusted EBITDA for Q1 2025 was $7.6 million, compared to an adjusted EBITDA loss of $7.3 million in Q1 2024 [16] - The company ended the quarter with approximately $59 million in cash and investments, and positive operating cash flow of $2.2 million [16] Business Line Data and Key Metrics Changes - The company activated 19 treatment centers in the U.S. by the end of Q1 2025, with plans to reach 30 active centers by year-end [6][7] - Average treatments per center were approximately two per month in Q1, with expectations to remain just under two for the remainder of the year [8][27] Market Data and Key Metrics Changes - The European market for ChemoSAT experienced a 29% growth over the prior quarter, reaching $1.8 million, although it is not expected to be a significant revenue contributor in the short to medium term [9] - The company is focusing on expanding its presence in the U.S. market while managing reimbursement challenges in Europe [9][40] Company Strategy and Development Direction - The company aims to leverage cash from operations to support research and development initiatives for Hebsado beyond metastatic uveal melanoma patients [6] - The strategy includes expanding treatment centers and enhancing access for patients through the Hepcido KidAccess 360 platform [8] - The company is pursuing additional clinical trials for liver-dominant metastatic colorectal and breast cancer, with FDA clearance received for both trials [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the goal of 30 active centers by year-end, with a balanced approach to center activations throughout the year [22][24] - The company anticipates that the average monthly treatment per site will stabilize just under two for the remainder of the year due to the pace of new center activations [27] - Management highlighted the importance of clinical demand and engagement with oncologists and interventional radiologists in driving revenue growth [13] Other Important Information - The company has no outstanding debt obligations and has successfully raised $16.2 million through the exercise of Series F warrants [16][17] - The company is managing its European operations on a breakeven basis while focusing on generating clinical data [43] Q&A Session Summary Question: Update on center activations and expectations for Q2 - Management indicated that center activations may be more evenly distributed throughout the year than previously anticipated, with potential for two to three additional centers in Q2 [20][24] Question: Treatment frequency and center performance - Average treatment frequency is expected to stabilize around 4.1 treatments per patient, with a mix of organic and referred patients contributing to center performance [35][86] Question: R&D expenses and EBITDA expectations - R&D expenses are expected to increase significantly, with EBITDA margins projected to remain positive throughout the year despite rising operational costs [29][30] Question: European market growth and reimbursement - Management noted that while the European market is growing, reimbursement challenges remain, and additional resources will be allocated once reimbursement is secured [39][42] Question: Companion diagnostics and potential acquisitions - The company is open to exploring companion diagnostics or synergistic products but has not identified any suitable opportunities at this time [70][72]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________ FORM 10-Q ______________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 06-1245881 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 566 Queensbury Avenue Queensbury, NY 12804 (Address of principal executive offices) (518) 743-8892 (Registrant's telephone number, including area code) For t ...

Core Viewpoint - Delcath Systems, Inc. (DCTH) shows potential for significant upside, with a mean price target of $22.60 indicating a 58.5% increase from the current price of $14.26 [1] Price Targets and Analyst Consensus - The average price target for DCTH ranges from a low of $21 to a high of $25, with a standard deviation of $1.82, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates a potential increase of 47.3%, while the highest suggests a 75.3% upside [2] - Analysts' price targets should be approached with caution, as they may not reliably predict actual stock price movements [3][7] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding DCTH's ability to report better earnings than previously predicted supports the view of potential upside [4] - A positive trend in earnings estimate revisions has been shown to correlate with stock price movements, indicating a potential for growth [11] - Over the last 30 days, one earnings estimate for DCTH has increased, leading to a Zacks Consensus Estimate rise of 134.2% [12] Zacks Rank and Investment Potential - DCTH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - The strong externally-audited track record of DCTH further supports its potential for near-term upside [13]

Company Overview - Atyr Pharma (ATYR) is part of the Medical sector, which includes 1012 individual stocks and currently holds a Zacks Sector Rank of 4, indicating its relative strength within the sector [2] - Atyr Pharma belongs to the Medical - Biomedical and Genetics industry, which consists of 510 individual stocks and is currently ranked 73 in the Zacks Industry Rank [6] Performance Metrics - Atyr Pharma has returned 6.9% year-to-date, outperforming the Medical sector's average return of 4.8% [4] - The Zacks Consensus Estimate for Atyr Pharma's full-year earnings has increased by 19.4% over the past quarter, reflecting stronger analyst sentiment and an improving earnings outlook [4] - The Medical - Biomedical and Genetics industry has gained an average of 6.3% year-to-date, indicating that Atyr Pharma is performing better than its industry peers [6] Comparative Analysis - Delcath Systems, Inc. (DCTH), another Medical stock, has outperformed the sector with a year-to-date return of 11.6% and a significant increase of 132.9% in its consensus EPS estimate over the past three months [5] - Delcath Systems operates in the Medical - Instruments industry, which has seen a decline of 3.5% year-to-date and is currently ranked 129 [7]

Corporate Presentation 2 NASDAQ: DCTH March 2025 Forward-Looking Statement The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potenti ...